ZVRA Zevra Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ZVRA

Price (delayed)

$4.52

Market cap

$196.29M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.3

Enterprise value

$197M

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes ...

Highlights
ZVRA's revenue has soared by 170% YoY and by 69% QoQ
ZVRA's gross profit has soared by 147% YoY and by 60% from the previous quarter
The quick ratio has dropped by 85% year-on-year and by 82% since the previous quarter
Zevra Therapeutics's net income has shrunk by 83% QoQ and by 72% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.kempharm.com
Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of ZVRA
Market
Shares outstanding
43.43M
Market cap
$196.29M
Enterprise value
$197M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.65
Price to sales (P/S)
5.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.17
Earnings
Revenue
$27.46M
EBIT
-$44.55M
EBITDA
-$43.54M
Free cash flow
-$33.83M
Per share
EPS
-$1.3
Free cash flow per share
-$0.95
Book value per share
$1.71
Revenue per share
$0.77
TBVPS
$2.78
Balance sheet
Total assets
$172.33M
Total liabilities
$110.46M
Debt
$43.77M
Equity
$61.86M
Working capital
$13.22M
Liquidity
Debt to equity
0.71
Current ratio
1.18
Quick ratio
1.15
Net debt/EBITDA
-0.02
Margins
EBITDA margin
-158.6%
Gross margin
89.3%
Net margin
-167.7%
Operating margin
-180.6%
Efficiency
Return on assets
-35.2%
Return on equity
-68.4%
Return on invested capital
-73%
Return on capital employed
-45.2%
Return on sales
-162.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ZVRA stock price

How has the Zevra Therapeutics stock price performed over time
Intraday
0%
1 week
0%
1 month
-20.98%
1 year
-12.74%
YTD
-30.99%
QTD
-22.07%

Financial performance

How have Zevra Therapeutics's revenue and profit performed over time
Revenue
$27.46M
Gross profit
$24.52M
Operating income
-$49.6M
Net income
-$46.05M
Gross margin
89.3%
Net margin
-167.7%
ZVRA's revenue has soared by 170% YoY and by 69% QoQ
ZVRA's gross profit has soared by 147% YoY and by 60% from the previous quarter
Zevra Therapeutics's net income has shrunk by 83% QoQ and by 72% YoY
The operating margin has soared by 57% YoY and by 34% from the previous quarter

Growth

What is Zevra Therapeutics's growth rate over time

Valuation

What is Zevra Therapeutics stock price valuation
P/E
N/A
P/B
2.65
P/S
5.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.17
Zevra Therapeutics's EPS has shrunk by 78% QoQ and by 67% YoY
Zevra Therapeutics's equity has decreased by 18% YoY and by 8% from the previous quarter
The price to book (P/B) is 9% lower than the last 4 quarters average of 2.9
ZVRA's revenue has soared by 170% YoY and by 69% QoQ
ZVRA's P/S is 54% below its last 4 quarters average of 12.6 and 35% below its 5-year quarterly average of 9.0

Efficiency

How efficient is Zevra Therapeutics business performance
ZVRA's ROE has shrunk by 149% YoY and by 92% QoQ
Zevra Therapeutics's return on invested capital has shrunk by 110% QoQ and by 28% YoY
The company's return on assets has shrunk by 63% QoQ and by 59% YoY
Zevra Therapeutics's return on sales has increased by 38% YoY but it has decreased by 12% QoQ

Dividends

What is ZVRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZVRA.

Financial health

How did Zevra Therapeutics financials performed over time
The total assets is 56% greater than the total liabilities
The total liabilities has soared by 175% YoY and by 54% from the previous quarter
The quick ratio has dropped by 85% year-on-year and by 82% since the previous quarter
ZVRA's debt is 29% smaller than its equity
Zevra Therapeutics's equity has decreased by 18% YoY and by 8% from the previous quarter
The debt to equity has grown by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.